Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival
Leonie K. de Klerk(Dana-Farber Cancer Institute), Adam J. Bass(Dana-Farber Cancer Institute), Eirini Pectasides, Anuj Patel(Harvard University), James M. Cleary(Brigham and Women's Hospital), Sarah Derks(Oncode Institute), Hui Zheng(Harvard University), Lauren K. Brais(Dana-Farber Cancer Institute), Douglas A. Rubinson(Harvard University), Melissa G Jean(Dana-Farber Cancer Institute), Charles S. Fuchs(University of Southern California), Jérémy Augustin(Université Paris Cité), Nadine J. McCleary(Harvard University), Nihal Raman(Dana-Farber Cancer Institute), Mariano Severgnini(Dana-Farber Cancer Institute), Patrick H. Lizotte(Harvard University), Mohamed Uduman(Dana-Farber Cancer Institute), Jeffrey W. Clark(Massachusetts General Hospital), Fahire G. Akarca(University of California, San Francisco), Peter C. Enzinger(Dana-Farber Cancer Institute), Amanda J. Rode(Dana-Farber Cancer Institute), Megan E. Cavanaugh(Dana-Farber Cancer Institute), Bridget Fitzpatrick(Dana-Farber Cancer Institute), Matthew Nazzaro(Dana-Farber Cancer Institute)
Cited by 30
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k